Loading clinical trials...
Loading clinical trials...
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Conditions
Interventions
avapritinib
regorafenib
Locations
114
United States
Mayo Clinic Cancer Center
Phoenix, Arizona, United States
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Rocky Mountain Cancer Centers
Boulder, Colorado, United States
Washington Hospital Center - Oncology and Hematology
Washington D.C., District of Columbia, United States
Mayo Clinic Cancer Center
Jacksonville, Florida, United States
Start Date
March 26, 2018
Primary Completion Date
March 9, 2020
Completion Date
September 15, 2021
Last Updated
October 6, 2022
NCT03050268
NCT06655246
NCT06441331
NCT03716089
NCT06759428
NCT05009927
Lead Sponsor
Blueprint Medicines Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions